Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist

被引:31
作者
Kummer, Nicole [1 ]
Benadiva, Claudio [1 ]
Feinn, Richard [2 ]
Mann, Jessica [1 ]
Nulsen, John [1 ]
Engmann, Lawrence [1 ]
机构
[1] Univ Connecticut Hlth Ctr, Ctr Adv Reprod Serv, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Farmington, CT 06030 USA
[2] Univ Connecticut Hlth Ctr, Dept Biostat, Farmington, CT 06030 USA
关键词
Estradiol; GnRH agonist; GnRH antagonist; ICSI; IVF; LH; OVARIAN HYPERSTIMULATION SYNDROME; IN-VITRO FERTILIZATION; HUMAN CHORIONIC-GONADOTROPIN; FOLLICLE-STIMULATING-HORMONE; HIGH-RISK PATIENTS; GNRH AGONIST; LUTEINIZING-HORMONE; ANTAGONIST; CYCLES; HCG;
D O I
10.1016/j.fertnstert.2011.04.050
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To determine factors predicting cycle success after in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) in high-risk patients undergoing controlled ovarian stimulation with a gonadotropin-releasing hormone (GnRH) antagonist protocol with a GnRH agonist to induce oocyte maturation. Design: Retrospective cohort study. Setting: University-based tertiary fertility center. Patient(s): Women who underwent a GnRH antagonist protocol during IVF-ICSI cycles and received a GnRH agonist for oocyte maturation. Intervention(s): GnRH-agonist trigger. Main Outcome Measure(s): Clinical and ongoing pregnancy rates and any occurrence of ovarian hyperstimulation syndrome (OHSS). Result(s): The serum luteinizing hormone (LH) level on the day of trigger of oocyte maturation was the single most important predictor of clinical pregnancy. Patients with a peak estradiol (E(2)) level >= 4,000 pg/mL also had statistically significant higher serum LH on the day of the GnRH-agonist trigger and had a higher clinical pregnancy rate compared with those with a peak E(2) level <4,000 pg/mL, although the two groups had comparable numbers of oocytes retrieved. No patients developed OHSS. Conclusion(s): Serum LH and E(2) levels >= 4,000 pg/mL on the day of the GnRH-agonist trigger are important predictors of success in patients at high risk of OHSS development. As none of the patients in this high-risk population developed OHSS, the GnRH-agonist trigger is effective in the prevention of this iatrogenic complication. (Fertil Steril (R) 2011;96:63-8. (C)2011 by American Society for Reproductive Medicine.)
引用
收藏
页码:63 / 68
页数:6
相关论文
共 28 条
[1]   Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates [J].
Acevedo, Belen ;
Gomez-Palomares, Jose Luis ;
Ricciarelli, Elisabetta ;
Hernandez, Eleuterio R. .
FERTILITY AND STERILITY, 2006, 86 (06) :1682-1687
[2]   STIMULATION OF AROMATIZATION OF EXOGENOUS AND ENDOGENOUS ANDROGENS IN OVARIES OF HYPOPHYSECTOMIZED RATS INVIVO BY FOLLICLE-STIMULATING-HORMONE [J].
ARMSTRONG, DT ;
PAPKOFF, H .
ENDOCRINOLOGY, 1976, 99 (04) :1144-1151
[3]   Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment:: a prospective randomized trial [J].
Babayof, R ;
Margalioth, EJ ;
Huleihel, M ;
Amash, A ;
Zylber-Haran, E ;
Gal, M ;
Brooks, B ;
Mimoni, T ;
Eldar-Geva, T .
HUMAN REPRODUCTION, 2006, 21 (05) :1260-1265
[4]   Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment [J].
Beckers, NGM ;
Macklon, NS ;
Eijkemans, MJ ;
Ludwig, M ;
Felberbaum, RE ;
Diedrich, K ;
Bustion, S ;
Loumaye, E ;
Fauser, BCJM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4186-4192
[5]   Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support [J].
Castillo, J. C. ;
Dolz, M. ;
Bienvenido, E. ;
Abad, L. ;
Casan, E. M. ;
Bonilla-Musoles, F. .
REPRODUCTIVE BIOMEDICINE ONLINE, 2010, 20 (02) :175-181
[6]   Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting [J].
DiLuigi, Andrea J. ;
Engmann, Lawrence ;
Schmidt, David W. ;
Maier, Donald B. ;
Nulsen, John C. ;
Benadiva, Claudio A. .
FERTILITY AND STERILITY, 2010, 94 (03) :1111-1114
[7]   Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation [J].
Eldar-Geva, Talia ;
Zylber-Haran, Edit ;
Babayof, Rachel ;
Halevy-Shalem, Tamar ;
Ben-Chetrit, Avraharn ;
Tsafrir, Avi ;
Varshaver, Irit ;
Brooks, Baruch ;
Margalioth, Ehud J. .
REPRODUCTIVE BIOMEDICINE ONLINE, 2007, 14 (02) :148-154
[8]   The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study [J].
Engmann, Lawrence ;
DiLuigi, Andrea ;
Schmidt, David ;
Nulsen, John ;
Maier, Donald ;
Benadiva, Claudio .
FERTILITY AND STERILITY, 2008, 89 (01) :84-91
[9]   GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS [J].
Engmann, Lawrence .
REPRODUCTIVE BIOMEDICINE ONLINE, 2006, 13 (05) :639-644
[10]   Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization [J].
Fauser, BC ;
de Jong, D ;
Olivennes, F ;
Wramsby, H ;
Tay, C ;
Itskovitz-Eldor, J ;
van Hooren, HG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :709-715